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Abstract
Individuals most often use several rather than one substance among alcohol, ciga-
rettes or cannabis. This widespread co-occurring use of multiple substances is
thought to stem from a common liability that is partly genetic in origin. Genetic risk
may indirectly contribute to a common liability to substance use through genetically
influenced mental health vulnerabilities and individual traits. To test this possibility,
we used polygenic scores indexing mental health and individual traits and examined
their association with the common versus specific liabilities to substance use.
We used data from the Avon Longitudinal Study of Parents and Children (N = 4218)
and applied trait-state-occasion models to delineate the common and substance-
specific factors based on four classes of substances (alcohol, cigarettes, cannabis and
other illicit substances) assessed over time (ages 17, 20 and 22). We generated
18 polygenic scores indexing genetically influenced mental health vulnerabilities and
individual traits. In multivariable regression, we then tested the independent contri-
bution of selected polygenic scores to the common and substance-specific factors.
Our results implicated several genetically influenced traits and vulnerabilities in the
common liability to substance use, most notably risk taking (bstandardised = 0.14; 95%
confidence interval [CI] [0.10, 0.17]), followed by extraversion (bstandardised = −0.10;
95% CI [−0.13, −0.06]), and schizophrenia risk (bstandardised = 0.06; 95% CI [0.02,
0.09]). Educational attainment (EA) and body mass index (BMI) had opposite effects
on substance-specific liabilities such as cigarette use (bstandardised-EA = −0.15; 95% CI
[−0.19, −0.12]; bstandardised-BMI = 0.05; 95% CI [0.02, 0.09]) and alcohol use
(bstandardised-EA = 0.07; 95% CI [0.03, 0.11]; bstandardised-BMI = −0.06; 95% CI [−0.10,
−0.02]). These findings point towards largely distinct sets of genetic influences on
the common versus specific liabilities.
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1 | INTRODUCTION
Substance use is a leading contributor to the global disease and dis-
ability burden1 and is associated with high societal and economic
costs. Of particular public health concern is the problematic use of
multiple substances, such as the co-occurring use of cigarettes, alco-
hol and cannabis. This pattern of co-occurrence has pervasive long-
term health implications.2 During adolescence and emerging adult-
hood, the initiation of use of multiple classes of substances may be
especially harmful, as it increases the risk of developing the clinical
manifestation of a substance use disorder.3 To inform prevention
strategies, it is therefore essential to understand the origins of such
problematic pattern of substance use.
According to the common liability model, the observed correla-
tions between the use of different substances2,4,5 can be explained
by the presence of a common, nonspecific liability underlying the
risk of use of different classes of substances.6,7 Support for this
model comes from several lines of research. For example, in obser-
vational studies, the use of different classes of substances is typi-
cally associated with a range of shared individual factors such as
mental health vulnerabilities (e.g., schizophrenia, attention deficit
and hyperactivity disorder [ADHD]),8,9 personality traits (e.g., risk
taking),10,11 cognitive factors (e.g., educational attainment),12 and
physical characteristics (e.g., body mass index [BMI]).13 Results
from twin4,14 and genomic studies15,16 further indicate that the
correlation between the use of different substances stems from a
common liability that is largely genetic in nature.
Evidence regarding the common liability model from genome-
wide association studies (GWAS) is more challenging to interpret. So
far, GWAS studies have most reliably identified single nucleotide poly-
morphisms (SNPs) that are associated with the use of particular clas-
ses of substances.16,17 For example, a replicated finding is the
association between the alcohol metabolism gene alcohol dehydroge-
nase 1B (ADH1B) and alcohol use16,18 or the association between the
nicotinic receptor gene CHRNA5 (cholinergic receptor nicotinic alpha
5 subunit) and cigarette use.16 While this evidence appears to impli-
cate only substance-specific genetic effects, recent powerful GWAS
studies also identified SNPs with effects shared across two classes of
substances (e.g., smoking and alcohol) and identified SNPs that extend
beyond ADH1B and CHRNA5.16 This highlights the importance of
systematically modelling factors that reflect common versus
substance-specific liabilities when assessing genetic influences on
substance use.
Genome-wide findings also implicate that different substance
use phenotypes share some polygenic liability with a number of
individual traits and vulnerabilities, such as risk taking,16,19,20
ADHD,16,20–22 depression,21–23 neuroticism,21 cognition20,22 or
schizophrenia.20–22,24,25 This body of research suggests that the
genetic architecture of the common liability may consist of highly
polygenic and small indirect effects via a range of genetically
influenced mental health vulnerabilities and individual traits. As such,
if those traits and vulnerabilities are causally involved in the aetiology
of the common liability to substance use, their respective genetic
proxies (e.g., genetic variants associated with risk taking) must be
associated with the common liability.
In this study, we propose to exploit the polygenic score (PGS)
approach to further interrogate the aetiology of the common and
substance-specific liabilities to substance use. A PGS is a continuous
index of an individual's genetic risk for a particular phenotype, based
on GWAS results for the corresponding phenotype.26 PGSs can be
used as genetic proxies indexing vulnerabilities and traits to study
their role in the common and specific liabilities to substance use.
Employing PGSs as proxies for potential risk factors can be conceived
as a first step in a series of genetically informed designs to strengthen
causal evidence in observational studies.27 For example, studies have
used PGSs indexing a particular vulnerability or trait, such as depres-
sion or psychotic disorders, to test their association with the use of
specific classes of substances including cannabis,28 alcohol,29,30 nico-
tine29,30 or illicit substances.29 However, this evidence does not pro-
vide insights regarding the aetiology of common versus substance-
specific liabilities. One study has employed the PGS approach to study
the effect of a few selected PGSs indexing mental health disorders on
the use of multiple substances.31 However, important traits and vul-
nerabilities previously implicated in the aetiology of substance use,
including personality traits, cognitive measures and physical character-
istics, remain to date untested.
We aimed to triangulate and extend previous phenotypic evi-
dence by integrating genomic data with phenotypic modelling of the
common versus specific liabilities to substance use in a longitudinal
population-based cohort. We first generated 18 PGSs, indexing a
range of genetically influenced mental health vulnerabilities and traits
previously implicated in the aetiology of substance use. Second, we
applied the PGS approach to test the association of the 18 genetically
influenced vulnerabilities and traits with (a) a common liability to sub-
stance use capturing the co-occurrence of use of alcohol, cigarettes,
cannabis and other illicit substances and (b) substance-specific liabili-
ties that are independent of the common liability. By applying geneti-
cally informed methods such as the PGS approach to study refined
phenotypes, this investigation has the potential to yield important
insights for the aetiology of substance use and inform prevention and
treatment programmes.
2 | METHODS AND MATERIALS
2.1 | Sample
We analysed data from the Avon Longitudinal Study of Parents and
Children (ALSPAC).32 Details about the study design, methods of data
collection, and variables can be found on the study website (http://
www.bristol.ac.uk/alspac/). We used phenotypic data on substance
use collected when the study participants were 17, 20 and 22 years
of age. Genotype data were available for 7288 unrelated children of
European ancestry after quality control (cf. Supporting information for
details). Participants were included if they had at least one available
substance use measure across the three time points, resulting in a
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final sample of 4218 individuals. Table S1 presents sample differences
between included and nonincluded individuals. Several sample charac-
teristics differed between included individuals and nonincluded indi-
viduals, but differences were small in magnitude (observed range
r = 0.01–0.22). Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local Research Ethics
Committees.
2.2 | Measures
2.2.1 | Substance use
Substance use (i.e., cigarette, alcohol, cannabis and other illicit sub-
stances) was measured at ages 17, 20 and 22. Severity of use of ciga-
rettes, alcohol and cannabis was assessed using validated self-report
questionnaires, namely, the Fagerstrom Test for Nicotine
Dependence,33 the Alcohol Use Disorders Identification Test34 and
the Cannabis Abuse Screening Test.35 For each scale, total scores
were calculated by adding up their item scores (cf. Supporting infor-
mation for details). For the use of other illicit substances, we com-
puted the total number of illicit substances used in the previous
12 months at each of the three time points (cf. Supporting information
for details).
2.2.2 | Summary statistics datasets
We collected summary statistics from 32 publicly available GWAS
derived from discovery cohorts, which did not include ALSPAC partic-
ipants (Table S2), indexing domains such as mental health vulnerabil-
ities (e.g., depression), personality (e.g., risk taking), cognition
(e.g., educational attainment), physical measures (e.g., BMI) and sub-
stance use (i.e., nicotine, alcohol and cannabis use). We chose GWAS
indexing either substance use behaviours or individual traits and vul-
nerabilities that could be plausibly linked to substance use
(cf. Section 1). From the initial 32 GWAS, we only included those with
a sufficiently large sample (N > 20 000 participants) and we excluded
several GWAS to avoid content overlap, resulting in a final selection
of 18 GWAS summary statistics (cf. Table S3 for further details). Ref-
erences for all GWAS studies used in the analysis and their character-
istics can be found in the Supporting information (Tables S2–S3).
2.3 | Statistical analyses
2.3.1 | PGS analysis
Eighteen PGSs were generated utilising PRSice software version 2.2
(http://www.prsice.info/),26 based on ALSPAC genotype data and the
selected GWAS summary statistics. The PGSs for each individual were
calculated as the sum of alleles associated with the phenotype of
interest (e.g., schizophrenia), weighted by their effect sizes found in
the corresponding GWAS. Clumping was performed in order to
remove SNPs in linkage disequilibrium (r2 > 0.10 within a 250-bp win-
dow). The PGSs were generated using a single p-value threshold of
1 in order to limit multiple testing while maximising the potential pre-
dictive ability of the PGSs.36
2.3.2 | Trait-state-occasion models of substance use
All analyses were conducted in R version 3.5.1 using the ‘Lavaan’
package.37 First, trait-state-occasion (TSO) structural equation models
were fitted using the scores for cigarette, alcohol, cannabis and other
illicit substance use at each time point.38 This approach enabled us to
model latent factors of substance use that are stable over time, includ-
ing (a) a common factor of all substances and (b) substance-specific
factors. Such advanced phenotypic modelling retains a higher degree
of precision and specificity compared with simple observed substance
use phenotypes. Missing data on the substance use indicators were
handled using full maximum likelihood estimation. The model parame-
ters were estimated using robust standard errors due to nonnormality
of the substance use scores. The TSO model was tested using avail-
able model specifications.39 Further details are provided in the
Supporting information and in Figure 1. Second, we tested the associ-
ations of each PGS with both the common and substance-specific
latent factors (single-PGS TSO models) in order to explore their indi-
vidual effects. False discovery rate (FDR) corrected p values40 are pro-
vided to account for multiple testing. Finally, we tested two sets of
multivariable TSO models (multi-PGSs TSO models) for each latent
factor, in which we included only those PGSs that remained significant
after FDR correction. In the first set, we included PGSs indexing sub-
stance use phenotypes (i.e., PGSs indexing dependency and frequency
of cigarette, cannabis and alcohol use). In the second set, we included
PGSs indexing mental health vulnerabilities and traits. The aim of this
multivariable approach was to assess the independent effect of each
PGS, controlling for potential pleiotropic effects (i.e., association of a
single PGS with an outcome explained by its genetic overlap with
other PGSs). All PGS-regression models were included directly within
the TSO models. An example of the Lavaan syntax used for the single
and multi-PGSs models can be found in the Supporting information.
All regression models were controlled for sex and population stratifi-
cation by including 10 principal components as covariates. All PGSs
were standardised.
3 | RESULTS
The descriptive statistics of substance use in our sample can be found
in Table S4. Correlations between the 18 PGSs and phenotypic mea-
sures of substance use are displayed in Figure 2 and provided in
Table S5. The TSO model of substance use fits the data well (χ2
(42) = 284.67, p < 0.001, Comparative Fit Index (CFI) = 0.952, Root
Mean Square Error of Approximation (RMSEA) = 0.037, Standardized
Root-Mean-Square Residual (SRMR) = 0.058). On average, the
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common factor accounted for 22% of the total variance in the sub-
stance use scores. The substance-specific factors explained 34% of
the variance. Remaining occasion-specific and residual variances are
shown inTable S6.
3.1 | Effects of the PGSs reflecting substance use
The standardised regression coefficients and confidence intervals of
the associations of the PGSs with the common and substance-specific
factors are shown in Figure 3 (cf. Tables S7 and S8). As expected, the
factors capturing cigarette and alcohol use were predicted by their
respective PGSs (e.g., frequency of cigarette/alcohol use), reflecting
specific genetic effects (e.g., linked to substance-specific metabolism).
The common factor was independently predicted by two substance
use PGSs (age of onset of cigarette use and alcohol frequency), in line
with evidence implicating age of onset of cigarette use as a liability
marker for initiation of use of other substances.41 Other substance-
specific factors were not predicted by their respective PGSs
(e.g., cannabis use factor). This could reflect the fact that the GWAS
used to derive those PGSs are only of limited power and have not yet
succeeded in identifying genetic variants that are substance-specific
in their biological function (e.g., metabolism).42
3.2 | Effects of the PGSs reflecting vulnerabilities
and protective traits
3.2.1 | Common factor of substance use
In the single-PGS TSO models, three PGSs (risk taking, extraversion
and schizophrenia) were associated with the common factor of sub-
stance use after FDR correction and when included in the multi-PGSs
TSO model (Tables S7 and S8, Figure 3). In the multi-PGSs model, the
PGS for risk taking exerted the largest independent effect
(bstandardised = 0.136, pFDR < 0.001), followed by the PGS indexing
extraversion (bstandardised = −0.095, pFDR < 0.001) and schizophrenia
(bstandardised = 0.056, pFDR = 0.003).
3.2.2 | Substance-specific factor: Cigarette use
In the single-PGS TSO models, five PGSs were associated with the
cigarette use factor following FDR correction (educational attainment,
F IGURE 1 The trait-state-occasion
model of the common and specific
liabilities to substance use. Note. The
simplified figure presents the observed
measures of substance use (squares) and
the latent factors (circles and elliptical
shapes). The factors at the bottom
represent substance-specific latent
factors. Variances of the latent factors are
not shown in the figure and were fixed to
1. Residual variances of the observed
variables (not represented) were freely
estimated. The estimates reported in the
figure represent the standardised factor
loadings of the model. o1, occasion factor
time 1; o2, occasion factor time 2; o3,
occasion factor time 3
F IGURE 2 Correlations between the polygenic scores and the
phenotype measures assessing substance use (cigarettes, alcohol,
cannabis and other illicit substances). Note. ADHD, attention deficit
hyperactivity disorder; BMI, body mass index. Blank cells represent
nonsignificant coefficients (p > 0.05). The correlation estimates and p
values are reported inTable S5. Included are 18 polygenic scores
(Rows 1–18) and 4 phenotype measures assessing substance use
(cigarettes, alcohol, cannabis and other illicit substances) across ages
17, 20 and 22 (Rows 19–22)
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F IGURE 3 Single-PGS and multi-PGSs trait-state-occasion models for the common and substance-specific factors. Note. The estimates
represent the standardised regression coefficients and confidence intervals of the single- and multi-PGSsTSO models. ADHD, attention deficit
hyperactivity disorder; BMI, body mass index; PGS, polygenic score; TSO, trait-state-occasion. Model A: PGSs indexing substance use
phenotypes. Model B: PGSs indexing individual vulnerabilities and traits. The explained variance can be obtained by taking the square of the
coefficients of the PGSs because both the PGSs and the factors are standardised to a mean of 0 and a variance of 1
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BMI, ADHD, depression and risk taking). In the multi-PGSs TSO
model, three PGSs remained associated with the cigarette use factor,
including educational attainment (bstandardised = −0.151, pFDR < 0.001)
with the largest effect, followed by BMI (bstandardised = 0.052,
pFDR = 0.007) and risk taking (bstandardised = 0.048, pFDR = 0.006).
3.2.3 | Substance-specific factor: Alcohol use
In the single-PGS TSO models, five PGSs were associated with the
alcohol use factor (extraversion, educational attainment, risk
taking, BMI and schizophrenia), all of which remained significant
following FDR correction and in the multi-PGSs TSO model. The
largest effect was found for extraversion (bstandardised = −0.118,
pFDR < 0.001), followed by educational attainment (bstandardised = 0.068,
pFDR < 0.001), risk taking (bstandardised = 0.063, pFDR = 0.002), BMI
(bstandardised = −0.055, pFDR = 0.009) and schizophrenia
(bstandardised = 0.049, pFDR = 0.014).
3.2.4 | Substance-specific factor: Cannabis use
None of the PGSs was associated with the cannabis use factor.
3.2.5 | Substance-specific factor: Other illicit
substance use
In the single-PGS TSO models, five PGSs were associated with the
factor representing other illicit substance use following FDR correc-
tion (educational attainment, BMI, extraversion, depression and
ADHD). In the multi-PGSs TSO model, three PGSs remained indepen-
dently associated, including educational attainment
(bstandardised = 0.121, pFDR < 0.001), extraversion (bstandardised = −0.085,
pFDR < 0.001) and BMI (bstandardised = −0.084, pFDR = 0.002).
4 | DISCUSSION
This study is the first genomic investigation using the PGS approach
to examine the contribution of a range of individual traits and vulnera-
bilities to both common and specific liabilities to substance use. We
highlight two important findings. First, our results implicate a number
of genetically influenced mental health vulnerabilities and personality
traits in the common liability to substance use, namely, PGSs indexing
high risk taking, low extraversion and schizophrenia liability. Second,
we identified a distinct set of risk factors that independently contrib-
uted to substance-specific liabilities, such as PGSs indexing educa-
tional attainment and BMI. In the following section, we will discuss
(a) insights for the aetiology of substance use, (b) findings regarding
the common liability, (c) findings regarding the substance-specific lia-
bilities, (d) implications for the prevention and treatment of substance
use and (e) limitations.
4.1 | Insights for the aetiology of substance use
In this study, we exploited the PGS approach as a genetically informed
method43 to strengthen inference on risk and protective factors
involved in liabilities to substance use, thereby enabling triangulation
of previous phenotypic evidence with distinct sources of bias
(e.g., traditional observational evidence). Using the PGS approach, our
results helped to tease apart some of the genetic predispositions
(e.g., PGS indexing schizophrenia liability) that indirectly contribute to
common and substance-specific liabilities to substance use. In particu-
lar, different sets of genetically influenced mental health vulnerabil-
ities and traits are likely to be involved in common versus substance-
specific liabilities. Importantly, all associations found in this study can
be conceptualised as indirect effects of genetically influenced traits
and vulnerabilities. To illustrate, our findings suggest that a genetic lia-
bility to risk taking could lead to greater risk-taking behaviour, which
in turn could affect an individual's propensity to engage in substance
use irrespective of the class of the substance. However, it should be
noted that the PGS approach relies on a number of key assumptions
(see Section 4.5). As such, we cannot rule out the possibility that con-
founders impact on the associations between PGSs and our substance
use outcomes.
4.2 | Risk and protective factors involved in the
common liability to substance use
Our results confirm previous findings of a common liability that partly
underlies the use of different classes of addictive substances, such as
cigarettes, alcohol, cannabis and other illicit substances.6,44 Regarding
its origins, our findings reveal that a genetic liability to high risk taking,
low extraversion and schizophrenia contributes to the common liabil-
ity to substance use. This corroborates previous phenotypic evidence,
which reported associations between substance use and similar traits
and vulnerabilities.8,10,11,45 Intriguingly, a genetic predisposition for
risk taking was most robustly associated with a common liability to
substance use, but only to a lesser extent with substance-specific lia-
bilities (cf. next paragraph). This indicates that individuals susceptible
to risk taking are more likely to use an array of different substances,
irrespective of their class. Similarly, a genetic predisposition to extra-
version was most strongly associated with the common liability to
substance use, whereas its associations with substance-specific liabili-
ties were weaker. Thus, high extraversion may protect against the use
of various substances. Furthermore, the common liability was
influenced by genetic risk for schizophrenia. Taken together, these
findings are in line with the notion that the use of various substances
could partly reflect a self-medication strategy for those individuals
more vulnerable to psychopathology and maladaptive personality
traits.46 This is in line with theories implicating the reward system as a
common pathway underlying the use of multiple substances—a sys-
tem altered in distressed individuals and for whom the use of sub-
stances may represent a mean to restore homeostasis.47 Finally, our
results suggest that shared genetic effects among different substances
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of use are substantially polygenic in nature, involving many genetic
variants exerting indirect and small effects (e.g., polygenic association
via risk taking). Future large GWAS may therefore benefit from
modelling a common liability to substance use, similar to recent
genome-wide attempts aiming to identify common genetic variation
underlying psychiatric traits.48,49
4.3 | Risk and protective factors involved in
substance-specific liabilities
Our results also showed that a substantial proportion of the pheno-
typic variation in substance use could not be explained by a common
liability. Using the PGS approach to identify genetically influenced risk
and protective factors involved in the substance-specific liabilities rev-
ealed three patterns of associations. First, (a) we identified a set of
factors that were linked to both the common liability to substance
use, as well as to substance-specific liabilities. Second, (b) several
factors were linked to substance-specific liabilities but did not
contribute to the common liability. Third, (c) some traits previously
implicated in substance use were not associated with any of the
substance-specific liabilities.
Regarding (a), we found that all factors involved in the common
liability including a genetic predisposition for risk taking, extraversion
and schizophrenia also contributed to the liability to alcohol use.
Hence, the aetiologies of these two liabilities (i.e., alcohol
vs. common) are partly based on overlapping risk factors. At the same
time (b), our results showed that two individual traits—BMI and edu-
cational attainment—were not linked to the common liability but
predicted substance-specific liabilities. Interesting results emerged
regarding the direction of the identified associations. For example, we
found that a predisposition for high educational attainment increased
the risk of alcohol and illicit substance use but reduced the risk of cig-
arette use. This is consistent with the notion that education makes
people less likely to smoke cigarettes50 due to an increased knowl-
edge of its adverse health consequences. At the same time, greater
education may provide more opportunities to consume alcohol and
access other substances, as indicated by previous observational evi-
dence.51 Opposite effects were also present for BMI. Here, a genetic
predisposition for high BMI increased the risk of cigarette use, while
reducing the risk of alcohol and other illicit substance use. The same
pattern of associations has been reported in observational studies.
For example, compared with normal weight adolescents, obese ado-
lescents were at reduced risk of alcohol and illicit substance use, but
had an elevated risk of cigarette use.13 As nicotine is known to sup-
press appetite, this may suggest that adolescents with a greater pre-
disposition to high BMI could smoke more in an attempt to control
their appetite.52
Finally (c), some of the previously implicated risk factors
(e.g., neuroticism and ADHD)9,10 were not associated with the com-
mon or substance-specific liabilities in our sample. First, this could
reflect a lack of power of the PGSs used in the analysis. However, we
used powerful PGSs (e.g., neuroticism, derived from a GWAS with
N > 160 000) that have been shown to predict rare outcomes in com-
parable samples.53 Second, some PGSs were associated with sub-
stance use liabilities only in less controlled models (e.g., ADHD and
depression predicting other illicit substance use only in single-PGS but
not multi-PGSs models). In addition to power issues, this may indicate
that the effects of ADHD/depression were explained by potentially
co-occurring traits that we included in our multivariable models.
4.4 | Implications for the prevention and treatment
of substance use
Our findings offer insights into the aetiology of substance use and
have relevant implications for the prevention and treatment of sub-
stance use. First, we identified a set of individual vulnerabilities and
traits, namely, risk taking, extraversion and schizophrenia, which con-
tributed to the general liability to substance use. Hence, prevention
and treatment programmes aiming to reduce substance use across
substances in adolescents may benefit from focusing on those vulner-
abilities and traits. For example, there is promising evidence from
randomised controlled trials showing reductions in substance use fol-
lowing interventions targeting abilities related to risk taking (e.g., self-
regulation) in adolescents.54 Our results also highlight that it is impor-
tant to target those individuals at greatest risk of developing a prob-
lematic pattern of substance use based on pre-existing vulnerabilities
such as schizophrenia. Hence, in adolescents with prodromal symp-
toms, particular emphasis may need to be placed on the prevention of
substance use. Finally, it is important to better understand the mecha-
nisms underlying some of the substance-specific associations found in
this study (e.g., high BMI as a risk factor for cigarette use) in order to
design more effective prevention and intervention strategies.
4.5 | Limitations
By using genetic proxies that are more robust to confounding,27 the
PGS approach retains key advantages over simple phenotypic associa-
tions. However, as with any inference method, the PGS approach
relies on a number of assumptions not directly testable
(e.g., horizontal pleiotropy and reverse causation). For example, dynas-
tic effects mean that the observed association between the child's
PGS and substance use outcomes may actually reflect environmen-
tally mediated genetic effects originating in the parents, rather than
genetic effects originating in the child. In this instance, the child PGS
is not an adequate proxy of the child vulnerability or trait. Employing
the PGS approach in within-family genetic designs can deal with sev-
eral of these limitations including dynastic effects55 and should be
considered in future. In addition, sensitivity analyses as part of Men-
delian randomisation methods are available and can help to assess
potential violations (e.g., certain forms of pleiotropy). Such analyses
will be possible once GWAS summary statistics for our outcomes of
interest (i.e., common and specific liabilities to substance use) are
available. Because our measures represent substance use behaviours,
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the findings cannot be generalised to specific substance use disorders.
It could be possible that the genetics of substance use is shared across
substances, whereas the genetics of substance use disorders might be
substance-specific and related to their specific pharmacology. Follow-
up investigations integrating other related liabilities are therefore
essential to further inform aetiological questions. These may include,
for instance, liabilities reflecting different facets of complex substance
use phenotypes (e.g., common liability to substance abuse or
dependence), different patterns of use (e.g., common liability to age of
onset of substance use and frequency of substance use), different
classifications of substances of use (e.g., abuse of stimulants
vs. depressants) or liabilities reflecting addictive behaviours more gen-
erally (e.g., gambling). It should also be noted that, unlike for alcohol,
cigarette and cannabis use, a validated clinical screening instrument
was not available in this sample for other illicit substances. This needs
to be considered when interpreting findings for this measure. Finally,
this study focused on a sample of young adults. Future research
should therefore expand to other age groups to assess if the contribu-
tion of some of the identified factors (e.g., risk taking) to substance
use is adolescent-delimited.
5 | CONCLUSION
Our findings reveal that distinct sets of genetically influenced vulnera-
bilities and protective factors are likely to be involved in the common
versus substance-specific liabilities to substance use. In particular, a
genetic predisposition to high risk taking, low extraversion and schizo-
phrenia may be associated with the individual's susceptibility to the
use of any type of substance. Additionally, genetic predispositions
related to educational attainment and BMI were related to the use of
multiple specific substances, although in opposite directions. Preven-
tion programmes in adolescents may benefit from focusing on these
vulnerabilities and protective factors.
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